Neurocrine Biosciences, Inc.: Initiation Of Coverage – Continued Investment & Growth for INGREZZA Paving The Way Forward? 

Neurocrine Biosciences Inc, a biopharmaceutical company specializing in neurologic, psychiatric, and endocrine related disorders, showed significant growth during its remarkable year of 2023. According to Neurocrine’s executives, the firm’s performance reflected the ongoing progress and the successful execution of business strategies with nearly 30% year-over-year sales growth for its flagship product, INGREZZA, which is a drug indicated for the treatment of tardive dyskinesia in adults.